Abstracts tagged "biologic response modifiers"

Abstract Number: 1898 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Loïc Choquette Sauvageau¹, Denis Choquette², Louis Bessette³, Isabelle Ferdinand¹, Boulos Haraoui⁴, Frédéric Massicotte¹, Jean-Pierre Pelletier², Jean-Pierre Raynauld², Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Édith Villeneuve¹ and Louis Coupal¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Institut de Rhumatologie de Montréal, Montreal, Canada, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…
Abstract Number: 2005 • ACR Convergence 2020
Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby², Giovanni Giorli², Alessandra Nerviani¹, Rebecca Hands², Liliane Fossati-Jimack², Georgina Thorborn², Myles Lewis¹ and Costantino Pitzalis², ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom
Background/Purpose: The results of the R4RA trial, the first biopsy-based RCT in TNF-i inadequate responders patients with Rheumatoid Arthritis (RA), showed that molecular stratification of…
Abstract Number: 2032 • ACR Convergence 2020
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…
Abstract Number: 0227 • ACR Convergence 2020
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Lucía Vega-Álvarez¹, Itziar Calvo-Zorrilla¹, Oihane Ibarguengoitia-Barrena¹, Juan M. Blanco-Madrigal¹, David Montero-Seisdedos², Carmen L. Garcia-Gomez¹, Maria Esther Ruiz-Lucea¹, Ana R. Inchaurbe-Pellejero¹, Ignacio Torre-Salaberri¹, Clara E. Perez-Velasquez¹, Olaia Fernandez-Berrizbeitia¹, Eduardo Cuende-Quintana³, Iñigo R. Gorostiza-Hormaetxe⁴, María Luz García-Vivar¹ and Eva Galindez-Agirregoikoa¹, ¹Basurto University Hospital, BILBAO, Spain, ²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ³Basurto University Hospital, Madrid, Spain, ⁴Basurto University Hospital, Bilbao
Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
Abstract Number: 0333 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis
Denis Choquette¹, Loïc Choquette Sauvageau², Louis Bessette³, Isabelle Ferdinand², Boulos Haraoui⁴, Frédéric Massicotte², Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard², Diane Sauvageau², Édith Villeneuve² and Louis Coupal², ¹Institut de Rhumatologie de Montréal, Montreal, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Laval University, Quebec, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: The treatment of psoriatic arthritis has evolved with the addition of agents targeting a different cytokine, Il-17 introduced in 2016. It has proven to…
Abstract Number: 0592 • ACR Convergence 2020
A Rheumatology-Driven Protocol and Treatment Algorithm of SARS-CoV-2 Cytokine Release Syndrome and Its Associated Outcomes
Sandy Lee¹, Neha Chiruvolu², Muntarin Karim³, Patil Injean⁴, Loomee Doo⁵, Donna Jose⁶, Deepa Panikkath¹, Micah Yu⁵, Anna Lafian⁵, Wendy De La Pena⁷, Albert Chow⁸, Karina Torralba⁹, Vaneet Sandhu¹⁰, Mehrnaz Hojjati⁵, Marven Cabling⁵ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA, ³Loma Linda University Health System, Loma Linda, CA, ⁴LOMA LINDA UNIVERSITY MEDICAL CENTER - RHEUMATOLOGY, Redlands, CA, ⁵Loma Linda University Medical Center, LOMA LINDA, CA, ⁶Loma Linda University Medical Center, Ontario, CA, ⁷PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Loma Linda University, San Bernardino, CA, ⁹Loma Linda University School of Medicine, Redlands, CA, ¹⁰Loma Linda University, Loma Linda, CA
Background/Purpose: The newly identified SARS-CoV-2 has brought Cytokine Release Syndrome (CRS) to a level of prominence not often seen in adult medicine. Mortality rates of…
Abstract Number: 0623 • ACR Convergence 2020
Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort
Neha Chiruvolu¹, Muntarin Karim², Patil Injean³, Sandy Lee³, Karina Torralba⁴, Christina Downey³, Mehrnaz Hojjati⁵, Loomee Doo⁵, Donna Jose⁶, Deepa Panikkath³, Micah Yu⁵, Anna Lafian⁵, Marven Cabling⁵ and Vaneet Sandhu⁷, ¹UC Riverside School of Medicine, Riverside, CA, ²Loma Linda University Health System, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University School of Medicine, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Loma Linda University Medical Center, Ontario, CA, ⁷Loma Linda University, Loma Linda, CA
Background/Purpose: Cytokine Release Syndrome (CRS) or Macrophage Activation Syndrome (MAS) is a life threating hyperinflammatory condition that can complicate rheumatic disease as well as infections…
Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Gabriele Simonini², Alessandra Bettiol³, Ilaria Pagnini⁴, Niccolò Lombardi⁵, Valerio Maniscalco⁶, Giada Crescioli⁵, Edoardo Marrani⁷, Roberto Bonaiuti⁵, Maria Vincenza Mastrolia⁸, Claudia Ravaldi⁹ and Alfredo Vannacci⁵, ¹Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ²Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, ³2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, ⁴1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, ⁵2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, ⁶1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, ⁷University of Florence, Firenze, Italy, ⁸Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁹3. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
Abstract Number: 050 • 2020 Pediatric Rheumatology Symposium
Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre
MANJARI AGARWAL ¹, Sujata Sawhney² and Anju Singh ³, ¹Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, ²Sir ganga ram hospital, Sector 37 noida, Uttar Pradesh, India, ³Sir Ganga Ram Hospital, delhi, India
Background/Purpose: The use of biologic response modifiers(BRMs) is associated with an increased risk of infections.We also use biosimilars for two reasons:1. originator not available, like…
Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Shubha Kollampare¹, C. Kent Kwoh^1,2, Wei-Hsuan Lo-Ciganic³, Lili Zhou^2,4, Erin L. Ashbeck² and Dominick Sudano¹, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, ⁴College of Pharmacy, University of Arizona, Tucson, AZ
Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…
Abstract Number: 206 • 2017 ACR/ARHP Annual Meeting
Real World IGRA Testing in Rheumatology Practice
Paul DeMarco^1,2, Megan Bishop³, Ashling Smith⁴, Herbert S. B. Baraf^1,5, Andrew Gregory DeMarco⁶, Temitope Ademola⁷, Deborah Contreras⁸, Adalisa Enriquez RMA¹, Lisa Klein¹, Kayra Perez¹, Sandra Ventura¹, Janice Whyte-Whitworth¹, Vince Calhoun¹, Theresa Bass Goldman¹ and Alan K Matsumoto^1,9, ¹The Center for Rheumatology and Bone Research, Wheaton, MD, ²Division of Rheumatology, Department of Medicine, Georgetown University School of Medicine, Washington, DC, ³Clinical Trials, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁴2730 University Blvd West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Department of Medicine, George Washington University School of Medicine, Washington, DC, ⁶Department of Biochemistry and Molecular Cellular Biology, Georgetown University Department of Biochemistry and Molecular Cellular Biology, Washington, DC, ⁷The Center for Rheumatology and Bone Research, Washington, DC, ⁸2730 University Boulevard West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁹Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Mycobacterium tuberculosis (MTb) screening is routine for clinical trial protocols, & authorization for immunomodulators use by health insurances. Real world data is needed to…
Abstract Number: 636 • 2017 ACR/ARHP Annual Meeting
Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials
Rochelle Castillo¹, Khushboo Sheth² and Santhanam Lakshminarayanan³, ¹University of Connecticut, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, University of Connecticut Health Center, Farmington, CT
Background/Purpose: Co-medication of MTX with TNF inhibitors (TNFi) has proven superior to TNFi monotherapy in improving clinical outcomes in patients with RA. Whether this holds…
Abstract Number: 2906 • 2017 ACR/ARHP Annual Meeting
Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries
Dominick Sudano¹, C. Kent Kwoh², Lili Zhou³, Erin L. Ashbeck⁴ and Wei-Hsuan Lo-Ciganic⁵, ¹University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ⁴The University of Arizona Arthritis Center, Tucson, AZ, ⁵Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Associate professor, TUCSON, AZ
Background/Purpose: Coccidioidomycosis (Cocci) is a fungal infection endemic to seven states in the US. Biologic response modifiers (BRMs) have been shown to increase the risk…
Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting
Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study
Carmen Bejerano¹, Natividad Oreiro¹, Carlos Fernandez-Lopez², Jose A Pinto-Tasende¹, Antonio Atanes¹, Bruno De Aspe¹, Genaro Graña Gil¹, Mercedes Freire¹, Manuel Acasuso³, Sonia Pertega⁴, Francisco J. de Toro¹ and Francisco J Blanco¹, ¹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ²Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, ³Centro de Salud San Jose, XAP Coruna, A Coruna, Spain, ⁴Epidemiology Unit, INIBIC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…
Abstract Number: 1350 • 2016 ACR/ARHP Annual Meeting
Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience
Usman Ajaz¹, Jeffrey R. Lisse², Neil M. Ampel³ and Dominick Sudano⁴, ¹Department of Medicine, University of Arizona, Tucson, AZ, ²Arizona Arthritis Center, University of Arizona, Tucson, AZ, ³Department of Infectious Disease, Southern AZ VA Medical Center, Tucson, AZ, ⁴Department of Rheumatology, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection that typically causes a self-limited pulmonary illness in the Southwestern United States,. Immunosuppressed patients are at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].